HCC1569 Cells
CAD$545.10*
Products are shipped frozen on dry ice in cryotubes. Each cryotube typically contains 3 × 106 cells for adherent lines or 5 × 106 cells for suspension lines (refer to the batch CoA for details).
General information
| Description | HCC1569 is a human breast cancer cell line derived from a primary ductal carcinoma. It exhibits a basal-like phenotype and is characterized as estrogen receptor (ER)-negative and HER2-positive, a molecular subtype with distinct clinical and therapeutic implications. Like other basal-like breast cancers, HCC1569 lacks expression of ER and progesterone receptor (PR), but it displays amplification and overexpression of the ERBB2 (HER2) oncogene, a key target for HER2-directed therapies. The cell line demonstrates a high degree of aneuploidy and harbors multiple genomic alterations relevant to breast cancer biology. HCC1569 is included in large-scale genomic profiling efforts such as the Cancer Cell Line Encyclopedia (CCLE) and related studies that integrate mutational, copy number, methylation, and expression data. These datasets have shown that HCC1569 carries structural variants and copy number amplifications consistent with aggressive breast tumors, including those involving HER2. Functional genomic screens have highlighted the dependency of this cell line on HER2 signaling pathways, supporting its use in evaluating HER2-targeted therapies and resistance mechanisms. Additionally, HCC1569 has been characterized for its HLA genotype and expression profile, which has implications for immunotherapy development. It is included in catalogs of HLA typing and neoantigen prediction, offering opportunities for exploring T cell epitope presentation and immune recognition in HER2-positive breast cancer contexts. This immunogenomic annotation makes HCC1569 a valuable resource not only for studying oncogenic signaling but also for evaluating tumor-immune interactions and designing personalized immunotherapies. |
|---|---|
| Organism | Human |
| Tissue | Breast |
| Disease | Breast ductal carcinoma |
| Synonyms | HCC-1569, Hamon Cancer Center 1569 |
Characteristics
| Age | 70 years |
|---|---|
| Gender | Female |
| Ethnicity | African American |
| Morphology | Epithelial |
| Cell type | Epithelial cell |
| Growth properties | Mixed: adherent and suspension |
Regulatory Data
| Citation | HCC1569 (Cytion catalog number 305784) |
|---|---|
| Biosafety level | 1 |
| NCBI_TaxID | 9606 |
| CellosaurusAccession | CVCL_1255 |
Biomolecular Data
| Protein expression | Estrogen receptor, negative; progesterone receptor, negative |
|---|---|
| Antigen expression | Epithelial glycoprotein 2 (EGP2); cytokeratin 19 |
| Oncogenes | Her2/neu+; p53- |
| Mutational profile | Mutation: BRCA2, Simple, p.Asn1100Thr (c.3299A>C), Heterozygous, BRCA2, Simple, p.Val1862fs*1 (c.5578delA), Heterozygous, FHIT, Simple, p.Val97Phe (c.289G>T) (651G>T), dbSNP=rs139666727, Heterozygous, Note=Germline. Mutation, PTEN, Simple, p.Lys267Argfs*9 (c.800delA) (p.Leu265fs, c.795delA), Heterozygous, TP53, Simple, p.Glu294Ter (c.880G>T), Heterozygous |
| Karyotype | Polyploid |
Handling
| Culture Medium | RPMI 1640, w: 2.0 mM stable Glutamine, w: 2.0 g/L NaHCO3 (Cytion article number 820700a) |
|---|---|
| Supplements | Supplement the medium with 10% FBS |
| Dissociation Reagent | Accutase |
| Doubling time | 45 hours |
| Fluid renewal | 2 to 3 times per week |
| Freeze medium | As a cryopreservation medium, we use complete growth medium (including FBS) + 10% DMSO for adequate post-thaw viability, or CM-1 (Cytion catalog number 800100), which includes optimized osmoprotectants and metabolic stabilizers to enhance recovery and reduce cryo-induced stress. |
| Thawing and Culturing Cells |
|
| Incubation Atmosphere | 37°C, 5% CO2, humidified atmosphere. |
| Shipping Conditions | Cryopreserved cell lines are shipped on dry ice in validated, insulated packaging with sufficient refrigerant to maintain approximately −78 °C throughout transit. On receipt, inspect the container immediately and transfer vials without delay to appropriate storage. |
| Storage Conditions | For long-term preservation, place vials in vapor-phase liquid nitrogen at about −150 to −196 °C. Storage at −80 °C is acceptable only as a short interim step before transfer to liquid nitrogen. |
Quality Control & Molecular Analysis
| Sterility | Mycoplasma contamination is excluded using both PCR-based assays and luminescence-based mycoplasma detection methods. To ensure there is no bacterial, fungal, or yeast contamination, cell cultures are subjected to daily visual inspections. |
|---|
Certificate of Analysis (CoA)
| Lot Number | Certificate Type | Date | Catalog Number |
|---|---|---|---|
| 305784-141025 | Certificate of Analysis | 05. Dec. 2025 | 305784 |